• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Medications in type-2 diabetics and their association with liver fibrosis

    2020-07-10 07:08:02MohamedTausifSiddiquiHinaAminRajatGargPravallikaChadalavadaWaelAlYamanRocioLopezAmandeepSingh
    World Journal of Gastroenterology 2020年23期

    Mohamed Tausif Siddiqui, Hina Amin, Rajat Garg, Pravallika Chadalavada, Wael Al-Yaman, Rocio Lopez,Amandeep Singh

    Abstract

    Key words: Diabetes medications; Anti-lipid medications; Antihypertensive medication;Fatty liver; Advanced fibrosis

    INTRODUCTION

    Non-alcoholic fatty liver disease (NAFLD) has been emerging as one of the most important cause of liver disease worldwide, and it is likely to become a leading cause of end-stage liver disease (ESLD) in the near future[1]. The global prevalence of NAFLD has been estimated to be around 25%, affecting nearly 1.8 billion individuals worldwide[2,3], of which 51.6 million are in the United States alone, representing 21.9%of adult United States population[4]. The pathological spectrum of NAFLD can range from benign hepatic steatosis to more severe forms such as non-alcoholic steatohepatitis (NASH), advanced fibrosis (AF), cirrhosis, and ESLD[5]. The subtype of NAFLD characterized by NASH is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death, and result in significant health-care and economic burden[6].

    As the epidemics of obesity and type 2 diabetes mellitus (T2D) increase worldwide,the prevalence of NAFLD is rising rapidly[6]. Recently T2D has been recognized as a major risk factor for progressive liver disease, with standardized mortality rates for cirrhosis greater than that for cardiovascular disease[7]. A study by Williamsonet al[8]showed that 56.9% patients with T2D had steatosis on ultrasonography. After excluding patients with secondary cause of steatosis, prevalence of NAFLD was 42.6%in their population[8]. Independent predictors for NAFLD in their patient population were body mass index (BMI), duration of diabetes, Hemoglobin A1c, triglyceride levels, and metformin use[8]. A meta-analysis of 17 studies involving 10897 patients concluded that the overall prevalence of NAFLD among patients with T2D is significantly higher and optimal management of T2D may play a role in preventing NAFLD[9]. Patients with T2D are usually on a number of prescription medications.These include oral hypoglycemics, insulin, anti-lipid and anti-hypertensive medications. It is known that diabetes mellitus is a risk factor for AF in NAFLD,however, not all NAFLD patients with diabetes develop AF. This may be due to effects of certain medications used to treat diabetes and dyslipidemia[10]. In one study the use of angiotensin converting enzyme (ACE) inhibitor was observed to reduce the risk of AF in chronic Hepatitis C patients[11]. There is paucity of data on the association of various medications with AF in patients with T2D, which is a well-known risk factor for advanced liver disease. The aim of this study was to assess the association of commonly used medications (anti-lipid, anti-diabetic and anti-hypertensive medications) with AF in patients with T2D and NAFLD.

    MATERIALS AND METHODS

    Study design

    This is a retrospective cohort study.

    Data source and patient selection criteria

    Our study protocol was approved by Institutional Review Board of the Cleveland Clinic. We used the International Classification of Disease 9thRevision Clinical Modification (ICD-9 CM) coding system and identified the patients with T2D (ICD 9 code: 250.xx) and suspected NAFLD (ICD 9 code: 571.8 and 571.9) from the Cleveland Clinic Electronic Medical Record System. We included patients who were 18 years or older and who underwent liver biopsy between January 1, 2000 to December 31, 2015.The decision to do liver biopsy was based on the clinical judgment of treating physician. Biopsies were reviewed by a group of expert gastroenterology and hepatology pathologists to detect fibrosis. Liver biopsies were classified according to NASH-CRN classification. Fibrosis was staged on a 5-point scale: Stage 0 = no fibrosis,stage 1 = zone 3 perisinusoidal/perivenular fibrosis, stage 2 = zone 3 and periportal fibrosis, stage 3 = septal/bridging fibrosis, and stage 4 = cirrhosis. AF was defined as fibrosis stage 3-4. We excluded the patients who did not have liver biopsy within 24 mo of T2D diagnosis, as well as, those with incomplete medical records or with secondary causes of hepatic steatosis {viral hepatitis, hemochromatosis, α1-antitrypsin deficiency, Wilson disease, lipodystrophy, starvation, on parenteral nutrition,abetalipoproteinemia, and using certain medications (corticosteroids, valproate, and antivirals)} were excluded. Patients were also excluded if they consumed more than 30 g of alcohol per day for males or more than 20 g per day for females. We collected age, gender, patient demographics including race, BMI, systolic and diastolic blood pressure, existing concurrent comorbidities such as hypertension, hyperlipidemia,laboratory results, medications and their duration of use.

    Statistical analysis

    We used Pearson’s chi-square (χ2) tests or Fisher’s Exact to analyze the differences in patient demographics. For continuous variables, we performed a one-way Analysis of Variance (ANOVA) or the non-parametric Kriskal Wallis tests. Findings are reported either as mean ± SD, median (25th, 75thpercentiles) or percentage. A multinomial logistic regression analysis was performed to identify the independent clinical factors associated AF. Age, gender, race, BMI, concurrent hypertension, hyperlipidemia,chronic kidney disease, inflammatory bowel disease, deep vein thrombosis, use of oral hypoglycemic medications, insulin, antihypertensive medications, antilipidemic medications, and aspirin were considered for inclusion in the logistic regression model and a stepwise variable selection method was used to choose the final model;variables withP< 0.10 were included in the final model. We adjusted for age, gender,race and BMI. SAS (Version 9.4, The SAS Institute, Cary, NC, United States) was used for all analyses and a two-sidedPvalue of less than 0.05 was considered to be statistically significant.

    RESULTS

    After applying inclusion and exclusion criteria, a total of 1183 subjects were identified and included in the final analysis. Out of these patients, 32.2% (n= 381) had AF(fibrosis score 3-4) on their liver biopsy. The demographics and clinical characteristics of participants are shown in Table 1. The mean age at liver biopsy for our cohort was 52 ± 11 years and 65.7% patients were female. The majority of patients were Caucasians (85.1%) followed by African American (9.2%) and other races (5.7%).Overall mean systolic and diastolic blood pressures (SBP and DBP) in our cohort were 129.6 ± 17.1 mmHg and 73.7 ± 11.0 mmHg, respectively. There was no difference in the SBP between the two fibrosis groups (129.5 ± 16.6vs129.9 ± 18.2,P= 0.66) but significant difference existed between the DBP in the two groups (74.5 ± 10.5vs72.1 ±11.7,P< 0.001). Hypertension and hyperlipidemia were more prevalent in Fibrosis 0-2 group (70%vs57.7%,P< 0.001; 68.2%vs49.1%,P< 0.001) whereas CKD was more prevalent in Fibrosis 3-4 group (4.6%vs13.6%,P< 0.001).

    In terms of medications in the AF group (n= 381), 51.7% were on oral hypoglycemic, 30.1% were on insulin, 65.4% were on antihypertensive and 37.3% on anti-lipidemic medications for a median duration of 17.4 mo, 8.3 mo, 18.1 mo, and 20.9 mo respectively. Table 2 presents a summary of medication use in our cohort. Figure 1 shows a visual representation of medication usage among the two groups.Unadjusted and adjusted odds ratio (OR) of clinical factors associated with AF have been listed in the Table 3. Amongst oral hypoglycemic medications, Metformin use was associated with decreased risk of AF [OR = 0.64 (0.49, 0.82),P< 0.001]. We did not find a statistically significant association between Glipizide (P= 0.75),Pioglitazone (P= 0.11) or Sitagliptin/Januvia (P= 0.79) and the presence of AF.Liraglutide use was also associated with decreased risk of AF [OR = 0.30 (0.14, 0.64),P= 0.002]. We did not find a statistically significant association between the use of Detemir/Levemir (P= 0.83), Lantus (P= 0.14), Humulin (P= 0.35) or Byetta (P= 0.65)and the presence of AF. Amongst anti-hypertensive medications, use of Lisinopril [OR= 0.74 (0.56, 0.97),P= 0.031] and Hydrochlorothiazide [OR = 0.57 (0.43, 0.76),P<0.001] were associated with decreased risk of AF. In contrast, use of Furosemide [OR =1.9 (1.4, 2.5),P< 0.001) and Spironolactone [OR = 3.1 (2.0, 4.6),P< 0.001] were associated with increased risk of AF. For other anti-hypertensive medications we did not find any statistically significant association. Amongst anti-lipidemics, use of Atorvastatin [OR = 0.62 (0.44, 0.86),P= 0.004] and Simvastatin [OR = 0.61 (0.44, 0.85),P= 0.003] were associated with decreased risk of AF. We did not find a statistically significant association for other anti-lipid agents.

    DISCUSSION

    This study is the first study in the literature exploring the association of different pharmacological modalities used in the treatment of T2D and AF in biopsy-proven NAFLD. Our study highlights the critical findings that certain prescription medications taken by patients with T2D are associated with decreased risk of AF.These medications might be playing a protective role by decreasing the rate of NAFLD progression. In our cohort of patients, oral hypoglycemic like metformin and liraglutide, anti-hypertensive medications like Lisinopril and Hydrochlorothiazide,and anti-lipid medication like Atorvastatin and Simvastatin are associated with decreased risk of AF, suggesting that they could perhaps have a protective effect on NAFLD.

    Diabetes is a known cause of NAFLD and advanced liver disease is the most common cause of deaths in patients with T2D, showing a reciprocal relationship between the two. Treatment approaches in T2D mainly include either decreasing insulin resistance (metformin, thiazolidinediones) or increasing circulating insulin levels (exogenous insulin or sulfonylureas)[10,12,13]. A study by Hazlehurstet al[14].explored the role of different classes of antidiabetic medications as a therapeutic disease modifying effect on NAFLD in patients with T2D. They specifically highlighted a promising role of metformin and GLP-1 agonists in treatment of NAFLD[14]. Our observation that Metformin is associated with a decrease in AF might suggests that insulin resistance is likely implicated in the pathophysiology of development of hepatic fibrosis. Metformin is effective as an anti-diabetic drug due to its ability to improve peripheral insulin sensitivity. Lowering blood glucose is achieved by decreasing gluconeogenesis in the liver, stimulating glucose uptake in the muscle, and increasing fatty acid oxidation in adipose tissue[15]. At the molecular level,some of the beneficial effects of metformin have been associated to the phosphorylation and nuclear export of Liver-kinase B1 which activates adenosine monophosphate-activated protein kinase, a regulator of energy metabolism, able to stimulate ATP-producing catabolic pathways (glycolysis, fatty acid oxidation, and mitochondrial biogenesis) and to inhibit ATP-consuming anabolic processes(gluconeogenesis, glycogen, fatty acid, and protein synthesis), leading to decreased glucose levels in the blood and ultimately decreased glucose mediated organ injury[16].A meta-analysis showed a 50% reduction in Hepatocellular carcinoma (HCC)incidence with metformin use (n= 8 studies; OR = 0.50, 95%CI: 0.34-0.73), further strengthening our observation that Metformin likely plays a protective role in liver disease[17]. In addition to Metformin, Liraglutide also showed a decreased risk of AF.Liraglutide is a glucagon-like-peptide 1 (GLP-1) analog that binds to the same receptors as the endogenous metabolic hormone GLP-1 and improves glucosehomeostasisviaits glucose-dependent stimulation of insulin secretion, inhibition of postprandial glucagon secretion and delayed gastric emptying[18]. A recent multicenter, double-blind, randomized, placebo-controlled phase 2 study published by Armstronget al[19]showed that 39% of the patients who received liraglutide and underwent end-of-treatment liver biopsy had resolution of definite NASH compared with 9% of the patients in the placebo group [relative risk 4.3 (95%CI: 1.0-17.7),P=0.01]. Also they noted that 9% of the patients in the liraglutide group had progression of fibrosis compared to 36% in the placebo group [0.2 (0.1-1.0),P= 0.04], further supporting the findings of our study.

    Table 1 Demographic and clinical characteristics

    Figure 1 Graphical presentation of differences in medication usage among patients in different fibrosis groups.

    Another observation made in our study was the protective role of Lisinopril, an angiotensin-converting enzyme, a medication commonly prescribed to lower blood pressure, in patients with T2D. A recent meta-analysis showed that renin angiotensin system inhibitors resulted in a marginally significant reduction in liver fibrosis score[MD = -0.30, 95%CI (-0.62, 0.02),P= 0.05] and a significant reduction in liver fibrosis area [MD = -2.36%, 95%CI (-4.22%, -0.50%),P= 0.01], hence concluding that these medications perhaps play a more protective role in liver disease[20]. Multiple animal studies have suggested that angiotensin II contributes to hepatic fibrosis by interacting with the angiotensin II receptor type 1 (AT1 receptor) leading to the activation of hepatic stellate cells-the main collagen producing cells in the liver[21-23].One animal model illustrated that inhibition of angiotensin II decreases the generation of reactive oxygen species, resulting in less collagen synthesis by hepatic stellate cells,and downregulates the vascular endothelial growth factor[24]. While another model suggested that angiotensin-receptor blockade leads to downregulation pro inflammatory/profibrotic cytokines[25], thus attenuating liver fibrosis. A study investigating the effect of Ramipril, an ACE inhibitor on the incidence of diabetes suggested that the use of ACE inhibitors may reduce the incidence of hyperglycemia in new diabetics as well as in those with insulin resistance[26]. Hence, this additional benefit that ACE inhibitors provide in diabetics may also contribute in part to the observed reduction in fibrosis in patients with NAFLD.

    Our data in a large cohort of well characterized patients with NAFLD also suggests that the use of statins like Atorvastatin and Simvastatin is associated with reduced risk of advanced hepatic fibrosis in NAFLD patients with T2D. In the presence of NAFLD and hyperinsulinemia, there is accumulation of lipid molecules in the liver which further leads to inflammation and lipotoxicity[27], playing a fundamental role in the pathogenesis of hepatic steatosis, steatohepatitis and fibrosis. Statins, the mainstay of lipid-lowering therapy, improves liver outcomes by lowering lipids and lipotoxicity[28]. Apart from that, statins have also been reported to reduce cardiovascular risks and mortality in patients with NAFLD[29]. In a Swedish study that explored changes in liver histology over time among patients with NAFLD, there was less fibrosis in patients prescribed a statin[30]. However, previous studies have concluded that statin should not be used for NASH alone without the association of dyslipidemia[31]. For the simplification of the medication classification furosemide and spironolactone were considered under antihypertensive group, while these medications do lower blood pressure, they are often used primarily as diuretics. It is possible that patients were receiving these medications for advanced liver disease associated fluid overload or ascites.

    The prevalence of NAFLD has progressively increased over the past 10 years,making it a significant health burden and the treatment of NAFLD is of prime concern to health care professionals and patients due to significant mortality and morbidity it implies[32]. Treatment is focused on lifestyle changes and managing the associated comorbidities. Lifestyle modification includes attention to patient’s diet by promoting intake of fruits and vegetables and avoiding high fat content; and increasing physical activity[33,34]. Obesity treating drugs like Orlistat and bariatric surgery may also help in selected cases in achieving weight loss that can help in NAFLD[34,35]. Other measures include insulin sensitizers, drugs that reduce blood lipids, glucagon-mimetics, drugs that may reduce fibrosis, angiotensin receptor blockers, and medicines believed to reduce endoplasmic reticular stress such as vitamin E, ursodeoxycholic acid, and Sadenosyl methionine[30]. Several newer agents such as Obeticholic acid and GFT505 have shown promising results and various other pharmacotherapies are still being studied[32]. Treatment options such as gene based therapeutic treatment of NAFLD in diabetics are still in the experimental phases, however they could offer promising therapeutic options in the near future[36].

    Our study has several limitations. It is a retrospective analysis and association does not imply causal relationship. In our multivariable analysis we adjusted for possible confounders, however, it is possible that one or more unknown confounders might be responsible for some of the results which we have observed. Since our studypopulation was recruited from a single center, generalization should be avoided. In addition, despite using the strict exclusion criteria, some degree of recall bias may have been present while evaluating for alcohol consumption and medication use. On the other hand, the large sample size of biopsy proven NAFLD patients is a major strength of the current study.

    Table 2 Medication use

    1Kruskal-Wallis test.2Pearson's χ2 test. Statistics presented as median (P25, P75) or n (%).

    In conclusion, in this large cohort of T2D with biopsy proven NAFLD, patients who were receiving Metformin, Liraglutide, Lisinopril, Hydrochlorothiazide, Atorvastatin and Simvastatin were less likely to have AF on liver biopsy while patients who were receiving Furosemide and Spironolactone had a higher likelihood of having AF on liver biopsies. Although our study does not indicate a causation it is important that physicians are aware of this key association. In the management and treatment of patients with NAFLD, clinicians should consider both liver disease and the associated metabolic co-morbidities. Along with diet and physical activity, focus should be given on specific pharmacological therapies that have been proven to be beneficial in NAFLD. Despite the consistent increase in the knowledge of therapeutic options for NAFLD, its management still remains a challenge for the scientific community and additional clinical trials are needed to evaluate the efficacy of various agents in NAFLD and T2D.

    Table 3 Assessment of associations between clinical factors and advanced fibrosis

    ARTICLE HIGHLIGHTS

    Research objectives

    We aimed to understand the association of the different pharmacologic modalities used in the treatment of diabetes mellitus on the progression of liver fibrosis in NAFLD patients with type-2 diabetes.

    Research methods

    We identified all adult patients with type-2 diabetes mellitus who underwent liver biopsy for suspected NAFLD at the Cleveland Clinic between January 1, 2000 to December 31, 2015. We retrospectively reviewed a cohort of 1183 patients with type-2 diabetes and biopsy proven NAFLD. We compared demographics, clinical characteristics, and differences in pattern of medication use in patients who had biopsy-proven NAFLD with and without advance fibrosis.A univariate and multivariate analysis was performed to assess the association of different classes of medication with and without the presence of AF.

    Research results

    We found that the patients who were receiving Metformin, Liraglutide, Lisinopril,Hydrochlorothiazide, Atorvastatin and Simvastatin were less likely to have AF on biopsy, while patients who were receiving furosemide and spironolactone were more likely to have AF when they underwent liver biopsy. Diabetic patients with chronic kidney disease were more likely to have AF on liver biopsy.

    Research conclusions

    Our study highlights the protective role of some of the commonly used medications in the treatment of type-2 diabetes mellitus. We propose that Metformin, Liraglutide, Lisinopril,Hydrochlorothiazide, Atorvastatin and Simvastatin may have a beneficial role in slowing down the progression of NAFLD.

    Research perspectives

    Although it is possible that some unknown confounding factors could have impacted our findings, this study lays a solid groundwork for future prospective studies to further investigate the protective role of these medications on the progression of liver fibrosis in diabetic patients with NAFLD.

    日本一本二区三区精品| 国产视频内射| 女生性感内裤真人,穿戴方法视频| 精品久久久久久久久亚洲 | netflix在线观看网站| 亚洲无线观看免费| 啦啦啦观看免费观看视频高清| 亚洲人成网站高清观看| 国产成人a区在线观看| 最近最新中文字幕大全电影3| 亚洲久久久久久中文字幕| 一卡2卡三卡四卡精品乱码亚洲| www.熟女人妻精品国产| 久久久精品大字幕| 搡老熟女国产l中国老女人| 免费看光身美女| 国产免费一级a男人的天堂| 黄色女人牲交| 日韩av在线大香蕉| 丰满人妻熟妇乱又伦精品不卡| 少妇熟女aⅴ在线视频| 村上凉子中文字幕在线| 免费看美女性在线毛片视频| 亚洲av电影不卡..在线观看| 白带黄色成豆腐渣| 91麻豆精品激情在线观看国产| 欧美成人性av电影在线观看| 一级av片app| 国产精品不卡视频一区二区 | 亚洲第一欧美日韩一区二区三区| 白带黄色成豆腐渣| 美女黄网站色视频| 麻豆国产av国片精品| 国产在线精品亚洲第一网站| 成年女人看的毛片在线观看| 国产精品三级大全| 熟女人妻精品中文字幕| 脱女人内裤的视频| 国内精品美女久久久久久| 国产精品久久久久久精品电影| 一个人观看的视频www高清免费观看| 成年女人毛片免费观看观看9| 色5月婷婷丁香| 国产三级中文精品| 偷拍熟女少妇极品色| 不卡一级毛片| 日韩欧美精品v在线| 嫩草影院精品99| 成人性生交大片免费视频hd| 日日摸夜夜添夜夜添小说| 99久久久亚洲精品蜜臀av| 精品午夜福利在线看| 性色avwww在线观看| 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 亚洲内射少妇av| 亚洲欧美日韩高清专用| 日韩欧美在线乱码| 亚洲成人中文字幕在线播放| 亚洲av电影在线进入| 琪琪午夜伦伦电影理论片6080| 久久久精品大字幕| 青草久久国产| 美女 人体艺术 gogo| 成年女人毛片免费观看观看9| 精品久久久久久久久久久久久| 亚洲欧美日韩高清在线视频| 国产在线男女| 国产精品乱码一区二三区的特点| 日韩精品中文字幕看吧| 日韩中文字幕欧美一区二区| 日韩欧美国产一区二区入口| 亚洲,欧美精品.| 十八禁人妻一区二区| 日韩欧美国产在线观看| 国内精品美女久久久久久| 欧美精品国产亚洲| 一进一出抽搐动态| 欧美+日韩+精品| 美女大奶头视频| 狠狠狠狠99中文字幕| 亚洲第一欧美日韩一区二区三区| 亚洲精品一卡2卡三卡4卡5卡| 国产免费av片在线观看野外av| 欧美成人a在线观看| 国内久久婷婷六月综合欲色啪| 国产黄片美女视频| 婷婷六月久久综合丁香| 久久午夜福利片| 国产aⅴ精品一区二区三区波| 全区人妻精品视频| 色综合站精品国产| 老司机午夜十八禁免费视频| 少妇高潮的动态图| 日本免费一区二区三区高清不卡| 黄片小视频在线播放| 欧美乱妇无乱码| 啦啦啦观看免费观看视频高清| 久久久久久九九精品二区国产| 成年女人永久免费观看视频| 欧美丝袜亚洲另类 | 两性午夜刺激爽爽歪歪视频在线观看| 热99在线观看视频| 99在线视频只有这里精品首页| 亚洲av中文字字幕乱码综合| 亚洲精品日韩av片在线观看| 色精品久久人妻99蜜桃| 亚洲第一电影网av| 国产高清视频在线播放一区| 亚洲精品粉嫩美女一区| 国产69精品久久久久777片| 日韩国内少妇激情av| 最新中文字幕久久久久| 欧美成狂野欧美在线观看| 免费观看精品视频网站| 午夜福利18| 日本a在线网址| 色av中文字幕| 一区二区三区激情视频| 亚洲性夜色夜夜综合| 人妻久久中文字幕网| 国产黄片美女视频| 成年女人永久免费观看视频| 亚洲第一欧美日韩一区二区三区| 999久久久精品免费观看国产| 久久精品影院6| 国产成人av教育| 一本综合久久免费| 国产私拍福利视频在线观看| 18禁黄网站禁片午夜丰满| 欧美日韩国产亚洲二区| 国产私拍福利视频在线观看| 亚洲成a人片在线一区二区| 日本熟妇午夜| 亚洲18禁久久av| bbb黄色大片| 欧美乱色亚洲激情| 88av欧美| 欧美丝袜亚洲另类 | 国产蜜桃级精品一区二区三区| 桃红色精品国产亚洲av| 国产精品不卡视频一区二区 | 亚洲在线观看片| 波多野结衣高清无吗| 最近中文字幕高清免费大全6 | av专区在线播放| 国产男靠女视频免费网站| 日日干狠狠操夜夜爽| 中文在线观看免费www的网站| 悠悠久久av| 欧美性猛交╳xxx乱大交人| 亚洲欧美精品综合久久99| 中文亚洲av片在线观看爽| 变态另类丝袜制服| 亚洲av不卡在线观看| 夜夜看夜夜爽夜夜摸| 九九热线精品视视频播放| 欧美3d第一页| 午夜福利在线观看免费完整高清在 | 亚洲国产色片| 白带黄色成豆腐渣| 欧美性猛交黑人性爽| 亚洲精品456在线播放app | 亚洲激情在线av| 99精品久久久久人妻精品| 搡老熟女国产l中国老女人| 男女做爰动态图高潮gif福利片| 日韩亚洲欧美综合| 黄色一级大片看看| 久久久久久久午夜电影| 色尼玛亚洲综合影院| 每晚都被弄得嗷嗷叫到高潮| 日日干狠狠操夜夜爽| av在线老鸭窝| 久久国产乱子伦精品免费另类| 午夜老司机福利剧场| 国产aⅴ精品一区二区三区波| 成人国产一区最新在线观看| 成人无遮挡网站| 99久久精品一区二区三区| 亚洲国产精品sss在线观看| 中国美女看黄片| 中文字幕av在线有码专区| 在线观看一区二区三区| 欧美xxxx性猛交bbbb| 又黄又爽又免费观看的视频| 丰满乱子伦码专区| 午夜久久久久精精品| 99久久久亚洲精品蜜臀av| 偷拍熟女少妇极品色| 99久久成人亚洲精品观看| 熟女电影av网| 国产精品久久久久久精品电影| 十八禁网站免费在线| www.www免费av| 成人亚洲精品av一区二区| 国产色婷婷99| 成人高潮视频无遮挡免费网站| 亚洲专区中文字幕在线| 他把我摸到了高潮在线观看| 精品免费久久久久久久清纯| 97超级碰碰碰精品色视频在线观看| 人妻丰满熟妇av一区二区三区| 国语自产精品视频在线第100页| 亚洲国产精品999在线| 综合色av麻豆| 99精品久久久久人妻精品| 99热精品在线国产| 两个人的视频大全免费| 国产一区二区三区在线臀色熟女| 国产成人a区在线观看| 日韩成人在线观看一区二区三区| 18禁黄网站禁片午夜丰满| 国语自产精品视频在线第100页| 国产一区二区激情短视频| 国产v大片淫在线免费观看| 精品一区二区三区人妻视频| 午夜亚洲福利在线播放| 真人做人爱边吃奶动态| 丰满人妻一区二区三区视频av| 老司机午夜十八禁免费视频| 1000部很黄的大片| 欧美成人一区二区免费高清观看| 欧美乱色亚洲激情| 久久精品综合一区二区三区| 亚洲人成网站高清观看| 亚洲精品成人久久久久久| 99精品久久久久人妻精品| 伦理电影大哥的女人| 色哟哟·www| 蜜桃久久精品国产亚洲av| 精品人妻偷拍中文字幕| 亚洲最大成人手机在线| 黄色日韩在线| 露出奶头的视频| 级片在线观看| 午夜福利欧美成人| 99久久精品国产亚洲精品| 亚洲人成网站在线播放欧美日韩| av视频在线观看入口| 日日摸夜夜添夜夜添小说| 久久婷婷人人爽人人干人人爱| 国产美女午夜福利| 亚洲国产高清在线一区二区三| 亚洲av一区综合| 天堂网av新在线| 精品久久久久久久久亚洲 | 国产av麻豆久久久久久久| 久久精品夜夜夜夜夜久久蜜豆| 成人性生交大片免费视频hd| 九九在线视频观看精品| 欧美成人性av电影在线观看| 色5月婷婷丁香| 亚洲av成人av| 久久人妻av系列| 亚洲精品成人久久久久久| 日韩 亚洲 欧美在线| 国产精品亚洲一级av第二区| 欧美激情在线99| 国产精品人妻久久久久久| 黄片小视频在线播放| 国产精品久久久久久久久免 | 高清毛片免费观看视频网站| 少妇高潮的动态图| 日本a在线网址| 精品久久久久久久人妻蜜臀av| 日韩欧美一区二区三区在线观看| 一级av片app| 在线观看av片永久免费下载| 性插视频无遮挡在线免费观看| 欧美日韩国产亚洲二区| АⅤ资源中文在线天堂| 国产 一区 欧美 日韩| 精品人妻视频免费看| 午夜精品久久久久久毛片777| 婷婷精品国产亚洲av| 日韩欧美免费精品| netflix在线观看网站| 一二三四社区在线视频社区8| 亚洲国产精品久久男人天堂| 男人舔女人下体高潮全视频| 色综合欧美亚洲国产小说| 神马国产精品三级电影在线观看| 成人av在线播放网站| 国语自产精品视频在线第100页| 国产亚洲欧美在线一区二区| 亚洲在线观看片| 久久精品夜夜夜夜夜久久蜜豆| 亚洲人成电影免费在线| 欧美日韩黄片免| 一个人观看的视频www高清免费观看| 中文资源天堂在线| 舔av片在线| 免费在线观看日本一区| 精品乱码久久久久久99久播| 在线播放国产精品三级| 美女免费视频网站| 两人在一起打扑克的视频| av在线蜜桃| www.www免费av| 少妇高潮的动态图| 日韩av在线大香蕉| 国产精品一区二区三区四区免费观看 | 国产精品一区二区性色av| 午夜福利在线观看吧| 两性午夜刺激爽爽歪歪视频在线观看| 制服丝袜大香蕉在线| av专区在线播放| 亚洲自偷自拍三级| 国产精品一区二区免费欧美| 国产91精品成人一区二区三区| 老司机福利观看| 亚洲美女黄片视频| 一边摸一边抽搐一进一小说| 国产毛片a区久久久久| 变态另类丝袜制服| 夜夜躁狠狠躁天天躁| 日韩欧美一区二区三区在线观看| 人妻久久中文字幕网| 久久国产乱子伦精品免费另类| 热99re8久久精品国产| 成年女人看的毛片在线观看| 久久九九热精品免费| 国产老妇女一区| 欧美黑人巨大hd| 亚洲最大成人中文| 欧美成人性av电影在线观看| 黄色一级大片看看| 啪啪无遮挡十八禁网站| 欧美不卡视频在线免费观看| 一个人观看的视频www高清免费观看| 国产免费男女视频| 国产伦人伦偷精品视频| 99国产精品一区二区三区| 亚洲狠狠婷婷综合久久图片| 亚洲午夜理论影院| 舔av片在线| 中文字幕高清在线视频| 一个人免费在线观看的高清视频| 少妇熟女aⅴ在线视频| 免费大片18禁| 熟妇人妻久久中文字幕3abv| 国产伦人伦偷精品视频| 人妻制服诱惑在线中文字幕| 成人午夜高清在线视频| 伊人久久精品亚洲午夜| 日韩欧美免费精品| 99国产精品一区二区三区| 日韩欧美免费精品| 人妻制服诱惑在线中文字幕| 亚洲国产精品成人综合色| 天天一区二区日本电影三级| 亚洲aⅴ乱码一区二区在线播放| 内射极品少妇av片p| 国产精品精品国产色婷婷| 国产欧美日韩精品一区二区| 国产av不卡久久| 看免费av毛片| 国产精品一区二区三区四区久久| 久久久国产成人精品二区| 欧美日韩综合久久久久久 | 少妇熟女aⅴ在线视频| 日韩欧美三级三区| 久久久国产成人精品二区| av中文乱码字幕在线| 日韩有码中文字幕| 国产精品影院久久| 97超级碰碰碰精品色视频在线观看| 97碰自拍视频| 日本黄色片子视频| 婷婷色综合大香蕉| 欧洲精品卡2卡3卡4卡5卡区| 久久久成人免费电影| 日本在线视频免费播放| 丰满人妻一区二区三区视频av| 国产aⅴ精品一区二区三区波| 我的女老师完整版在线观看| 高清在线国产一区| 久久99热这里只有精品18| 亚洲男人的天堂狠狠| 久久精品夜夜夜夜夜久久蜜豆| 色综合欧美亚洲国产小说| 中文字幕人成人乱码亚洲影| 日本在线视频免费播放| 一进一出好大好爽视频| 一本精品99久久精品77| 91麻豆精品激情在线观看国产| 中文在线观看免费www的网站| 91麻豆精品激情在线观看国产| 国产大屁股一区二区在线视频| 午夜a级毛片| 欧洲精品卡2卡3卡4卡5卡区| 久久婷婷人人爽人人干人人爱| 在线播放国产精品三级| 日韩欧美三级三区| 国产精品电影一区二区三区| 亚洲最大成人av| 91九色精品人成在线观看| 偷拍熟女少妇极品色| 欧美绝顶高潮抽搐喷水| 天美传媒精品一区二区| 欧美不卡视频在线免费观看| 国产成人影院久久av| 熟女电影av网| 简卡轻食公司| 亚洲精品一区av在线观看| 国产成人欧美在线观看| 国产不卡一卡二| 一卡2卡三卡四卡精品乱码亚洲| 国内揄拍国产精品人妻在线| 中文字幕人妻熟人妻熟丝袜美| 国产私拍福利视频在线观看| 国产探花在线观看一区二区| 亚洲无线在线观看| 色5月婷婷丁香| 亚洲av第一区精品v没综合| 99久久九九国产精品国产免费| 夜夜爽天天搞| 国产亚洲精品久久久久久毛片| 男人的好看免费观看在线视频| 999久久久精品免费观看国产| 一级作爱视频免费观看| 一进一出抽搐gif免费好疼| 三级毛片av免费| 色在线成人网| 色尼玛亚洲综合影院| 99热只有精品国产| 窝窝影院91人妻| 亚洲狠狠婷婷综合久久图片| 黄色配什么色好看| 性色avwww在线观看| 亚洲中文字幕一区二区三区有码在线看| 麻豆成人午夜福利视频| 2021天堂中文幕一二区在线观| 女人被狂操c到高潮| 午夜a级毛片| 丰满人妻熟妇乱又伦精品不卡| 精品人妻1区二区| av女优亚洲男人天堂| 亚洲精品亚洲一区二区| 免费在线观看成人毛片| 美女大奶头视频| 久久伊人香网站| 国产成年人精品一区二区| 窝窝影院91人妻| 欧美性感艳星| 黄色日韩在线| 国产淫片久久久久久久久 | 禁无遮挡网站| 嫩草影视91久久| 成人鲁丝片一二三区免费| 久久精品久久久久久噜噜老黄 | 亚洲国产高清在线一区二区三| 一级作爱视频免费观看| 精品久久久久久,| 国产成人啪精品午夜网站| 日韩欧美三级三区| 99久久99久久久精品蜜桃| 亚洲av第一区精品v没综合| 亚洲专区国产一区二区| 成人性生交大片免费视频hd| 精品人妻视频免费看| 丰满人妻熟妇乱又伦精品不卡| 国产精品一区二区三区四区久久| 午夜免费男女啪啪视频观看 | 亚洲无线在线观看| 黄色一级大片看看| 久久午夜亚洲精品久久| 2021天堂中文幕一二区在线观| 精品99又大又爽又粗少妇毛片 | 欧美乱妇无乱码| 国产三级中文精品| 欧美另类亚洲清纯唯美| 日本精品一区二区三区蜜桃| 真人做人爱边吃奶动态| 欧美zozozo另类| 精品国产亚洲在线| 99久久精品国产亚洲精品| av欧美777| 欧美一级a爱片免费观看看| 亚洲狠狠婷婷综合久久图片| h日本视频在线播放| 日韩亚洲欧美综合| 久久国产乱子伦精品免费另类| 日本在线视频免费播放| 国产三级黄色录像| 成人国产综合亚洲| 久久久国产成人免费| 自拍偷自拍亚洲精品老妇| 日本三级黄在线观看| 国产av不卡久久| 熟妇人妻久久中文字幕3abv| 一本久久中文字幕| 免费看a级黄色片| 别揉我奶头 嗯啊视频| 国产av不卡久久| 欧美激情国产日韩精品一区| 午夜免费激情av| 国产三级中文精品| 国产成人啪精品午夜网站| 国产国拍精品亚洲av在线观看| 好看av亚洲va欧美ⅴa在| 久久天躁狠狠躁夜夜2o2o| 成人av一区二区三区在线看| 国产成人欧美在线观看| 亚州av有码| 中文资源天堂在线| 最后的刺客免费高清国语| 欧美+亚洲+日韩+国产| 校园春色视频在线观看| 久久人人爽人人爽人人片va | or卡值多少钱| 在线观看66精品国产| bbb黄色大片| 久久精品夜夜夜夜夜久久蜜豆| 亚洲三级黄色毛片| 免费看美女性在线毛片视频| 中文亚洲av片在线观看爽| 国内精品久久久久久久电影| www.色视频.com| 赤兔流量卡办理| 18禁在线播放成人免费| 国产视频一区二区在线看| 一级黄片播放器| 日本 av在线| 免费人成在线观看视频色| 91在线精品国自产拍蜜月| 欧美三级亚洲精品| 久久99热6这里只有精品| 欧美午夜高清在线| 色综合婷婷激情| 欧美成人a在线观看| 在线观看av片永久免费下载| 老鸭窝网址在线观看| 中文字幕av成人在线电影| 校园春色视频在线观看| 国产一区二区激情短视频| 伦理电影大哥的女人| 日韩有码中文字幕| 婷婷六月久久综合丁香| 在线国产一区二区在线| 18美女黄网站色大片免费观看| 日韩精品青青久久久久久| 国产av一区在线观看免费| 中文字幕熟女人妻在线| av天堂中文字幕网| 一级黄片播放器| 欧美午夜高清在线| 色5月婷婷丁香| 毛片女人毛片| 18禁黄网站禁片免费观看直播| 日韩大尺度精品在线看网址| 狠狠狠狠99中文字幕| 每晚都被弄得嗷嗷叫到高潮| 亚洲男人的天堂狠狠| 美女高潮喷水抽搐中文字幕| 午夜精品一区二区三区免费看| 亚洲熟妇中文字幕五十中出| 级片在线观看| 亚洲av.av天堂| 国产大屁股一区二区在线视频| 美女黄网站色视频| 黄色丝袜av网址大全| 每晚都被弄得嗷嗷叫到高潮| av视频在线观看入口| 小说图片视频综合网站| 最近在线观看免费完整版| 亚洲真实伦在线观看| 如何舔出高潮| 国产91精品成人一区二区三区| 亚洲欧美日韩高清在线视频| av在线天堂中文字幕| 99久久九九国产精品国产免费| 日韩高清综合在线| 两个人的视频大全免费| 免费在线观看亚洲国产| 一级a爱片免费观看的视频| 99热这里只有精品一区| 久久99热这里只有精品18| 老女人水多毛片| 九色成人免费人妻av| 午夜日韩欧美国产| 嫩草影院新地址| 变态另类成人亚洲欧美熟女| 真人一进一出gif抽搐免费| 亚洲真实伦在线观看| 91麻豆av在线| 国产欧美日韩一区二区三| 人妻丰满熟妇av一区二区三区| 欧美性猛交╳xxx乱大交人| 国产白丝娇喘喷水9色精品| 男人和女人高潮做爰伦理| 99国产极品粉嫩在线观看| 两人在一起打扑克的视频| 一区福利在线观看| 国产成人a区在线观看| 色综合站精品国产| 欧美绝顶高潮抽搐喷水| 国产精品久久视频播放| 悠悠久久av| 精品熟女少妇八av免费久了| 国产三级中文精品| 成人鲁丝片一二三区免费| 久久久成人免费电影| 国产伦精品一区二区三区四那| 免费看美女性在线毛片视频| 黄色一级大片看看| 性色avwww在线观看| 国产高潮美女av| 成人鲁丝片一二三区免费| 亚洲激情在线av| 国产av麻豆久久久久久久| 最近中文字幕高清免费大全6 | 国产成人啪精品午夜网站| 一二三四社区在线视频社区8| 国产精品不卡视频一区二区 |